ClinicalTrials.gg
CompletedNCT00511108Updated May 12, 2017Results posted

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

A Phase 1 interventional study of Comparator: sitagliptin phosphate and Comparator: pioglitazone in Type 2 Diabetes Mellitus (T2DM), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
68th of 197
211 · median 102
Started
2007
with 16 others
Phase 1
23 of 198
none open now
Registered
32nd of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 68th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 23 in phase 1, and was the 32nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A clinical study to determine the safety, efficacy and mechanism of action of sitagliptin alone and in combination with pioglitazone, in patients with type 2 diabetes mellitus who have inadequate glycemic (blood sugar) control.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has type 2 diabetes mellitus
  • Male
  • Female that is highly unlikely to become pregnant
  • Patient is not on an antihyperglycemic agent (AHA) ( [A1C] 7-10%) or on oral single AHA or low-dose combination therapy (A1C 6.5-9.0%)

Exclusion criteria

Exclusion Criteria:

  • Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis
  • Patient has required insulin therapy within the past 12 weeks
  • Patient is on or has been taking a Peroxisome Proliferator-Activated Receptor-gamma (PPAR -gamma) agent (i.e. Thiazolidinediones [TZDs]) within the prior 12 weeks of the screening visit.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    1

    Arm 1: drug

    Drug: Comparator: sitagliptin phosphate · Drug: Comparator: placebo to pioglitazone

  • Active comparator
    2

    Arm 2: active comparator

    Drug: Comparator: pioglitazone · Drug: Comparator: placebo to sitagliptin

  • Experimental
    3

    Arm 3: drug + active comparator

    Drug: Comparator: sitagliptin phosphate · Drug: Comparator: pioglitazone

  • Placebo comparator
    4

    Arm 4: placebo comparator

    Drug: Comparator: placebo to pioglitazone · Drug: Comparator: placebo to sitagliptin

Interventions

  • sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.

  • pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

  • DrugComparator: placebo to pioglitazone

    pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

  • DrugComparator: placebo to sitagliptin

    sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glucagon 3-hour Total Area Under the Curve (AUC) After 12 Weeks of Treatment

    Glucagon concentration was measured at 9 points during an Meal Tolerance Test (MTT), at times -10, 0, 10, 20, 30, 60, 90, 120, and 180 minutes. Total AUC was calculated over 3 hours including all sample points starting from 0 minutes using the trapezoid method. The change from baseline reflects Week 12 total AUC minus the Week 0 total AUC.

    Time frame: Baseline and 12 weeks

  2. Percent Change From Baseline in Index of Static Beta-cell Sensitivity to Glucose After 12 Weeks of Treatment

    Static sensitivity is a measure of the effect of glucose on beta cell secretion and is the ratio between the insulin secretion rate and glucose concentration above the threshold level at steady state. Percent change from baseline was calculated as the difference between index of static sensitivities at Week 12 and at baseline with respect to the index of static sensitivity at baseline times 100.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change From Baseline in Glucose 5-hour Total AUC After 12 Weeks of Treatment

    Glucose concentration was measured at 11 points during an Meal Tolerance Test (MTT), at times -10, 0, 10, 20, 30, 60, 90, 120, 180, 240, 300 minutes. Total AUC was calculated over 5 hours including all sample points starting from 0 minutes using the trapezoid method. The change from baseline reflects Week 12 total AUC minus the Week 0 total AUC.

    Time frame: Baseline and 12 weeks

07

Results

Posted Mar 5, 2010

Participant flow

First Patient In: 12-Sep-2007; Last Patient Last Visit: 24-Feb-2009 Forty-four medical clinics worldwide (17 in the United States, 20 in Europe, 4 in Australia, and 3 in Israel).

Participant flow — Overall Study
MilestoneSitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlacebo
Started52545253
Completed46524748
Not completed6255
Withdrew: Adverse event2012
Withdrew: Lost to follow-up0210
Withdrew: Physician decision0001
Withdrew: Withdrawal by subject4032

Outcome measures

PrimaryChange From Baseline in Glucagon 3-hour Total Area Under the Curve (AUC) After 12 Weeks of Treatment

Glucagon concentration was measured at 9 points during an Meal Tolerance Test (MTT), at times -10, 0, 10, 20, 30, 60, 90, 120, and 180 minutes. Total AUC was calculated over 3 hours including all sample points starting from 0 minutes using the trapezoid method. The change from baseline reflects Week 12 total AUC minus the Week 0 total AUC.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · pg*hr/mL
Change From Baseline in Glucagon 3-hour Total Area Under the Curve (AUC) After 12 Weeks of Treatment
pg*hr/mLSitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlacebo
Change From Baseline in Glucagon 3-hour Total Area Under the Curve (AUC) After 12 Weeks of Treatment-17.2 (-30.1 to -4.2)-4.9 (-18.1 to 8.3)-29.8 (-43.6 to -16.1)12.5 (-1.9 to 26.9)
Statistical analysis
  • Sitagliptin 100 mg vs Placebo · ANCOVA · p = 0.002 · Mean difference (net): -29.7 · 95% CI -48.7 to -10.6Model terms: treatment, prior diabetes pharmacotherapy (yes or no), and baseline value as a covariate
PrimaryPercent Change From Baseline in Index of Static Beta-cell Sensitivity to Glucose After 12 Weeks of Treatment

Static sensitivity is a measure of the effect of glucose on beta cell secretion and is the ratio between the insulin secretion rate and glucose concentration above the threshold level at steady state. Percent change from baseline was calculated as the difference between index of static sensitivities at Week 12 and at baseline with respect to the index of static sensitivity at baseline times 100.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Index of Static Beta-cell Sensitivity to Glucose After 12 Weeks of Treatment
Percent ChangeSitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlacebo
Percent Change From Baseline in Index of Static Beta-cell Sensitivity to Glucose After 12 Weeks of Treatment71.5 (46.8 to 100.3)27.0 (7.8 to 49.7)125.2 (87.2 to 171.0)-2.3 (-17.4 to 15.5)
Statistical analysis
  • Sitagliptin 100 mg vs Placebo · ANCOVA · p = <0.001 · Geometric mean difference: 73.8 · 95% CI 44.2 to 104.4The outcome was analyzed by ANCOVA on the log scale. Results have been back-transformed to the original scale.
SecondaryChange From Baseline in Glucose 5-hour Total AUC After 12 Weeks of Treatment

Glucose concentration was measured at 11 points during an Meal Tolerance Test (MTT), at times -10, 0, 10, 20, 30, 60, 90, 120, 180, 240, 300 minutes. Total AUC was calculated over 5 hours including all sample points starting from 0 minutes using the trapezoid method. The change from baseline reflects Week 12 total AUC minus the Week 0 total AUC.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · mg*hr/dL
Change From Baseline in Glucose 5-hour Total AUC After 12 Weeks of Treatment
mg*hr/dLSitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlacebo
Change From Baseline in Glucose 5-hour Total AUC After 12 Weeks of Treatment-209.8 (-281.6 to -138.0)-245.6 (-316.6 to -174.6)-389.2 (-463.6 to -314.7)18.6 (-58.2 to 95.4)
Statistical analysis
  • Sitagliptin 100 mg + Pioglitazone 30 mg vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -407.8 · 95% CI -513.4 to -302.1Model terms: treatment, prior diabetes pharmacotherapy (yes or no), and baseline value as a covariate

Adverse events

Collected over Weeks 0-12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg—1/52 (1.9%)3/52 (5.8%)
Pioglitazone 30 mg—0/54 (0%)3/54 (5.6%)
Sitagliptin 100 mg + Pioglitazone 30 mg—1/52 (1.9%)0/52 (0%)
Placebo—0/53 (0%)9/53 (17%)
Most frequent serious events
Most frequent serious events
EventSitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlacebo
Tibia fractureInjury, poisoning and procedural complications0/520/541/520/53
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/520/540/520/53
Most frequent other events
Most frequent other events
EventSitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlacebo
HyperglycaemiaMetabolism and nutrition disorders3/520/540/520/53
Upper respiratory tract infectionInfections and infestations0/523/540/523/53
Blood glucose increasedInvestigations0/520/540/523/53
HeadacheNervous system disorders0/520/540/523/53

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlaceboTotal
Mean54.6 ± 7.653.4 ± 7.853.3 ± 8.653.3 ± 7.753.6 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlaceboTotal
Female2431182194
Male28233432117
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Sitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlaceboTotal
White45434948185
Black693220
Asian11024
Other01012
Glucose 5-hour (hr) Total area under the curve (AUC)
Glucose 5-hour (hr) Total area under the curve (AUC)(mg*hr/dL)Sitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlaceboTotal
Mean1179.9 ± 322.81250.6 ± 349.61276.0 ± 348.51255.1 ± 290.91240.4 ± 328.4
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percent)Sitagliptin 100 mgPioglitazone 30 mgSitagliptin 100 mg + Pioglitazone 30 mgPlaceboTotal
Mean7.7 ± 0.87.9 ± 0.97.9 ± 0.98.0 ± 1.17.9 ± 1.0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Alba M, Ahren B, Inzucchi SE, Guan Y, Mallick M, Xu L, O'Neill EA, Williams-Herman DE, Kaufman KD, Goldstein BJ. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Diabetes Obes Metab. 2013 Dec;15(12):1101-10. doi: 10.1111/dom.12145. Epub 2013 Jul 19. PubMed 23782502 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2007 to primary completion in Feb 2009, 19 months.

Results were first posted in Mar 2010, 1 year after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 19 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2007
First posted
Aug 3, 2007
StartActual
Jul 11, 2007
Primary completionActual
Feb 24, 2009
CompletionActual
Feb 24, 2009
Results first posted
Mar 5, 2010
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00511108
Responsible party
Sponsor
First posted
Aug 3, 2007
Start date
Jul 11, 2007
Primary completion
Feb 24, 2009
Completion
Feb 24, 2009
Results posted
Mar 5, 2010
Last update
May 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Pioglitazone

Start the discussion